A phase 1 randomized study evaluating the effect of omeprazole on the pharmacokinetics of a novel 5-hydroxytryptamine receptor 4 agonist, revexepride (SSP-002358), in healthy adults

BACKGROUND: About 30% of patients with gastroesophageal reflux disease continue to experience symptoms despite treatment with proton pump inhibitors. The 5-hydroxytryptamine 4 receptor agonist revexepride (SSP-002358) is a novel prokinetic that stimulates gastrointestinal motility, which has been su...

Descripción completa

Detalles Bibliográficos
Autores principales: Pierce, David, Corcoran, Mary, Velinova, Maria, Hossack, Stuart, Hoppenbrouwers, Mieke, Martin, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354395/
https://www.ncbi.nlm.nih.gov/pubmed/25767373
http://dx.doi.org/10.2147/DDDT.S64621

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354395/
https://www.ncbi.nlm.nih.gov/pubmed/25767373
http://dx.doi.org/10.2147/DDDT.S64621

Ejemplares similares